KICK-IN GOAL - IDORSIA | Real-time Bid/Ask 09:47:19 29/05/2024 BST | ||
| 40.45 CHF / 40.95 CHF | +2.91% |
|
| Current month | +20.40% | ||
| 1 month | +8.95% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
IDORSIA LTD
| Date | Price | Change |
|---|---|---|
| 28/05/24 | 39.55 | +0.25% |
| 27/05/24 | 39.45 | +1.28% |
| 24/05/24 | 38.95 | -1.39% |
| 23/05/24 | 39.5 | -3.07% |
| 22/05/24 | 40.75 | +5.03% |
Delayed Quote Swiss Exchange
Last update May 28, 2024 at 04:20 pm
More quotesStatic data
| Product type | Reverse Convertibles |
|---|---|
| Buy / Sell | CALL |
| Underlying | IDORSIA LTD |
| Issuer | UBS |
| KOMSDU | |
| ISIN | CH1274478374 |
| Date issued | 05/07/2023 |
| Strike | 6.51 CHF |
| Maturity | 05/07/2024 (38 Days) |
| Parity | 0.01 : 1 |
| Emission price | 100 CHF |
| Emission volume | N/A |
| Settlement | both |
| Currency | CHF |
Technical Indicators
| Highest since issue | 93.5 CHF |
|---|---|
| Lowest since issue | 28.54 CHF |
| Spread | 5 CHF |
| Spread % | 1.24% |
Company Profile
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Sector
-
Consensus: Idorsia Ltd
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
2.25
CHF
Average target price
1.692
CHF
Spread / Average Target
-24.78%
- Stock Market
- Certificates
- KOMSDU Certificat
